Table 2.
Drug Resistance Profile of Recombinants
| Date | Site of origina | Variants, Nb | Resistance mutations | Drug resistance interpretation |
|---|---|---|---|---|
| 7-00 | Plasma | 1 | K103N, M184V, G190S | NNRTI-R, 3TC-R |
| CVL | 3 | K103N | NNRTI-R | |
| CVL | 1 | K103N, M184V | NNRTI-R, 3TC-R | |
| CVL | 1 | M41T, K103N, M184V | NNRTI-R, 3TC-R | |
| 2-01 | Plasma | 1 | K103N, M184V, G190S | NNRTI-R, 3TC-R |
| Plasma | 1 | M184V, G190S | NNRTI-R, 3TC-R | |
| 7-01 | Plasma | 1 | M41L, M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R |
| Plasma | 1 | M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R | |
| Plasma | 2 | M184V, G190S | NNRTI-R, 3TC-R | |
| 2-02 | Plasma | 2 | M41L, M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R |
| 7-02 | Plasma | 2 | M184V, G190S, T215S | NNRTI-R, 3TC-R |
| Plasma | 1 | K101E, G190S | NNRTI-R | |
| 1-03 | Plasma | 1 | M41L, K101E, M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R |
| Plasma | 1 | M41L, M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R | |
| Plasma | 1 | K101E, M184V, G190S, T215F | NNRTI-R, AZT-R, 3TC-R | |
| 6-03 | Plasma | 1 | K103N | NNRTI-R |
| 12-03 | Plasma | 1 | M41L, K103N, G190S, T215F | NNRTI-R, AZT-R |
| Plasma | 1 | M41L | None |
a
Sequences were obtained from both plasma and CVL samples at the February and July 2000 visits. For later visits, viral loads were <80 copies/ml in the CVL, precluding sequence analysis.
b
An average of 12 (range 7–17) variants were analyzed from each time point from July 2000 to December 2003 for the presence of recombination. Only the recombinant variants are characterized in the table.
NNRTI, nonnucleoside reverse transcriptase inhibitor; 3TC, lamivudine; AZT, zidovudine; R, high level resistance.